Daily Management Review

Patrick Vallance, GSK’s head of research, set to become UK’s scientific advisor


11/03/2017


The move comes in the wake of GSK’s new Chief Executive Emma Walmsley undertaking a major overhaul of the company’s pharmaceuticals division with a focus on boosting productivity at the company.



On Friday, a source familiar with the matter at hand stated, Patrick Vallance, the research and development head of GlaxoSmithKline will assume the position of the new scientific advisor to the British government and leave the company.
 
The planned departure comes just three months after Emma Walmsley, GSK’s new CE announced a major overhaul in the pharmaceuticals division saying the group’s performance in drug development needs to be sharper by adopting a sharper commercial focus.
 
Vallance, who joined GSK in 2006 and has been the president of its R&D division since January 2012, has yet to officially resign. In the event of his resignation, GSK will be obliged to issue a statement since he is also a member of its board.
 
The Financial Times has reported Vallance’s exit from GSK.
 
GSK declined to comment.
 
The British government was not immediately available for comment.
 
Vallance, who at one time taught was the professor of medicine at University College London, will replace Mark Walport as the senior science adviser to the prime minister.
 
It is not yet clear when he will assume his new role.
 
Earlier this year, Walmsley had poached Luke Miels from AstraZeneca as her new head of pharmaceuticals. Miels is expected to play a key role in driving up productivity at the company.
 
Incidentally, GSK has lagged behind rivals in recent years and has suffered a number of high-profile clinical trial failures on Vallance’s watch, which have undermined faith in its R&D skills.
 
In her bid to turn around the company, in July Walmsley had said she would narrow the focus the group’s drug researching efforts and ditch more than 30 drug development projects.
 
GSK intends to allocate 80% of its R&D budget to respiratory and HIV/infectious diseases, along with two other potential areas of oncology and immuno-inflammation.
 
Walmsley’s turnaround plans have drawn investors’ concerns as they aren’t fully convinced and worry that the pursuing them would be at the cost of dividends and the group’s consumer healthcare portfolio.
 
 
References:
www.reuters.com







Science & Technology

UK trials new breathing aid developed by Mercedes Formula One

Uber sues Los Angeles authorities over user data collection

Google Introduces New Coronavirus Website

WHO Warns That The Youth Are ‘Not Invincible' To The Novel Coronavirus

Chinese software company learns to recognize 95% of masked faces

World's largest retailer to use 5G for medical services

SpaceX Receives Approval To Create Research & Manufacturing Facility In Los Angeles

JPMorgan: Transition to e-money will be based on blockchain

Tesla In Advance Talks With CATL For Using Lithium Batteries

Financial giants and US government turn to quantum computers

World Politics

World & Politics

Aerospace Consortium To Build Ten Thousand Ventilator In Britain

US Ambassador To UK Holds China Responsible For Global Spread Of Coronavirus

China to lift quarantine in Wuhan on April 8

British Government Hires Former Nestle’s Executive For ‘War Room’ Food Security

Canada, Australia refuse to send athletes to Olympics 2020

Plans For A Possible Delay Of Olympics Being Formulated By Tokyo Organizers: Reuters

Maduro says Venezuela will receive UN assistance to fight coronavirus

2 Million Masks For Coronavirus Crisis In Europe Donated By Jack Ma